IC
LKFT

Ikarian Capital’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Ikarian Capital’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-100,000
Closed -$6.89M – 235
2021
Q2 		$6.89M Hold
100,000
– – 0.56% 50
2021
Q1 		$7.71M Buy
+100,000
New +$9.21M 0.26% 82
2020
Q2 		– Sell
-35,000
Closed -$6.86M – 186
2020
Q1 		$6.86M Buy
+35,000
New +$7.53M 0.52% 51

Other funds holding LKFT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Ikarian Capital's LKFT Position: Q3 2022 in Review

Ikarian Capital sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q3 2022, closing a stake of 86,865 shares — an estimated $4.83M sold.

Ikarian Capital first reported a position in LKFT in Q1 2021 and held it in 6 quarters. The position peaked at $15.5M in Q1 2021. 84 funds tracked by Wall St. Rank hold LKFT as of Q3 2022.

  • Ikarian Capital reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q3 2022 after selling out during the quarter.
  • Ikarian Capital sold 86,865 Lakefront Biotherapeutics American Depositary Shares shares in Q3 2022, an estimated $4.83M.
  • Ikarian Capital first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2021 and held it in 6 quarters.
  • Ikarian Capital's Lakefront Biotherapeutics American Depositary Shares position peaked at $15.5M in Q1 2021.
  • 84 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2022.

Based on Ikarian Capital's 13F filing for Q3 2022, filed 14 Nov 2022.